The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery

Advancing from level II to level III AI agents in precision medicine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research.1-3 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Enrique Velazquez-Villarreal, MD, PhD, MPH, MS
Assistant professor, Department of Integrative Translational Sciences, Beckman Research Institute, City of Hope Comprehensive Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain, UCLA-led review finds

Artificial intelligence may help radiologists identify subtle signs of breast cancers that are missed during routine mammograms—and some AI systems may even identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram—but there are still many significant limitations, according to a review led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Guest Editorial

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
By Richard L. Schilsky, H. Kim Lyerly, Thomas R. Fleming and Renzo Canetta
Byline
Enrique Velazquez-Villarreal, MD, PhD, MPH, MS
Assistant professor, Department of Integrative Translational Sciences, Beckman Research Institute, City of Hope Comprehensive Cancer Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account